Case number 1:22-cv-00083
Novartis Pharmaceuticals Corporation v. Teva Pharmaceuticals USA, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 25, 2022 | 26 | Notice of Service (16) Docket Text: NOTICE OF SERVICE of Plaintiff's Initial Infringement Chart for U.S. Patent No. 11,058,667 and Plaintiff's First Supplemental Infringement Chart for U.S. Patent No. 11,096,918 against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jul 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Scheduling Conference is now set for 8/3/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:22-cv-00032-RGA et al.(nms) |
| Jun 15, 2022 | 24 | Proposed Order (21) Docket Text: PROPOSED Scheduling Order (with disputed provisions), by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/15/2022 (nms). |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order Extending Time to submit a Proposed Scheduling Order to June 15, 2022. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 10, 2022 | 23 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION and Proposed Order Extending Time to submit Proposed Scheduling Order to June 15, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 9, 2022 | 22 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to June 10, 2022 - filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Jun 9, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to June 10, 2022. Signed by Judge Richard G. Andrews on 6/9/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to June 8, 2022. Signed by Judge Richard G. Andrews on 6/2/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| Jun 1, 2022 | 20 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME the parties' deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 8, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to and including June 1, 2022. Signed by Judge Richard G. Andrews on 5/26/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 25, 2022 | 19 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to June 1, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. Signed by Judge Richard G. Andrews on 5/19/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 18, 2022 | 18 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME deadline to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 25, 2022. - filed by Crystal Pharmaceutical (Suzhou) Co., Ltd.. (Gattuso, Dominick) |
| May 11, 2022 | 17 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to May 18, 2022 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,, Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| May 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to May 18, 2022. Signed by Judge Richard G. Andrews on 5/11/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 to May 11, 2022. Signed by Judge Richard G. Andrews on 5/5/2022. Associated Cases: 1:20-md-02930-RGA et al.(nms) |
| May 4, 2022 | 16 | Stipulation to EXTEND Time (9) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in these actions concerning U.S. Patent Nos. 11,058,667; 9,517,226; 9,937,143; and 11,135,192 in accordance with the Court's oral order at the April 21, 2022 status conference to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 27, 2022 | 15 | Answer to Counterclaim (8) Docket Text: ANSWER to [13] Answer to Complaint, and Counterclaims, by Novartis Pharmaceuticals Corporation.(Silver, Daniel) Modified on 4/27/2022 (nms). |
| Apr 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:21-cv-01330-LPS et al. (ntl) |
| Apr 7, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jeanna M. Wacker and Mark C. McLennan for Teva Pharmaceuticals USA, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 6, 2022 | 14 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Other Affiliate Teva Pharmaceutical Industries Ltd., Other Affiliate Capital Research Global Investors for Teva Pharmaceuticals USA, Inc. filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) |
| Apr 6, 2022 | 13 | Answer to Complaint (20) Docket Text: ANSWER to [1] Complaint, Affirmative Defenses, and COUNTERCLAIMS against Novartis Pharmaceuticals Corporation, by Teva Pharmaceuticals USA, Inc..(Hoeschen, Nathan) Modified on 4/8/2022 (nms). |
| Apr 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [12] MOTION for Pro Hac Vice Appearance of Attorney Mark C. McLennan and Jeanna M. Wacker filed by Teva Pharmaceuticals USA, Inc. Signed by Judge Leonard P. Stark on 4/5/22. (ntl) |
| Apr 5, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher E. Loh for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 4, 2022 | 12 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Mark C. McLennan and Jeanna M. Wacker - filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) |
| Apr 4, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christina Schwarz and Nicholas N. Kallas for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 4, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Jared L. Stringham for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Apr 1, 2022 | 11 | Status Report (9) Docket Text: Joint STATUS REPORT by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 29, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: The Court observes that this case is marked as related to one or more other cases now pending before another judge of this Court. Accordingly, IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than April 1, submit a joint status report, providing their position(s) as to which judge this case should be reassigned to. ORDERED by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [7] STIPULATION and Order to dismiss defendant Teva Pharmaceutical Industries Ltd. -- Party Teva Pharmaceutical Industries Ltd. terminated. Signed by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (9 in 1:22-cv-00186-LPS, 9 in 1:22-cv-00083-LPS, 10 in 1:22-cv-00032-LPS) MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 3/29/22. Associated Cases: 1:22-cv-00032-LPS, 1:22-cv-00083-LPS, 1:22-cv-00186-LPS (ntl) |
| Mar 29, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [8] STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint (D.I. 1) to April 6, 2022 filed by Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc. Signed by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS et al. (ntl) |
| Mar 23, 2022 | 9 | Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, J (4) |
| Mar 23, 2022 | 9 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, Jared L. Stringham)(Joyce, Alexandra) |
| Mar 22, 2022 | 8 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to move, plead, or otherwise respond to the Complaint (D.I. 1) to April 6, 2022 - filed by Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) |
| Mar 15, 2022 | 7 | Stipulation (4) Docket Text: Joint STIPULATION to dismiss defendant Teva Pharmaceutical Industries Ltd. by Teva Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) |
| Mar 15, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:20-md-02930-RGA. (ntl) |
| Mar 2, 2022 | 6 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Teva Pharmaceuticals USA, Inc. served on 3/1/2022, answer due 3/22/2022. (Joyce, Alexandra) |
| Jan 26, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Jan 21, 2022 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (nmg) |
| Jan 21, 2022 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (nmg) |
| Jan 21, 2022 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,058,667. (nmg) |
| Jan 21, 2022 | 3 | ANDA Form (2) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: No earlier than 12/10/2021. Date of Expiration of Patent: 5/9/2036.Thirty Month Stay Deadline: No earlier than 7/7/2023. (nmg) |
| Jan 21, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Jan 21, 2022 | 1 | Civil Cover Sheet (2) |
| Jan 21, 2022 | 1 | Exhibit A (16) |
| Jan 21, 2022 | 1 | Main Document (12) Docket Text: COMPLAINT for PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3786259.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(nmg) |
| Jan 21, 2022 | 1 | Complaint* (1) |
